News | Ultrasound Imaging | October 19, 2017

Study of over 200 patients found CEUS achieve correct diagnosis with 97 percent accuracy, without radiation and at lower cost

Contrast-Enhanced Ultrasound Safe and Effective Detector of Liver Cancer

October 19, 2017 — Doctors can effectively detect liver cancer with ultrasound and tiny microbubbles, according to a study announced at the International Contrast Ultrasound Society (ICUS) 32nd Annual Conference, Oct. 5-6 in Chicago. This technique allows detection without radiation, expensive magnetic resonance imaging (MRI) equipment or biopsies.

The imaging technique, known as contrast-enhanced ultrasound (CEUS), "is an exciting option because it provides a more cost-effective and less-invasive way for accurately characterizing the tumor," said Stephanie Wilson, M.D., a professor of radiology at the University of Calgary and study author.

The study of over 200 patients at risk for hepatocellular carcinoma, the most common liver cancer and the second leading cause of cancer deaths worldwide, found that CEUS imaging using the microbubbles allowed for the correct diagnosis with 97 percent accuracy.

CEUS uses liquid suspensions of tiny gas microbubbles to improve the clarity and reliability of an ultrasound image. The microbubbles are smaller than red blood cells and, when they are injected into a patient's arm vein, they flow through the microcirculation and reflect ultrasound signals, improving the accuracy of diagnostic ultrasound exams. The microbubbles are expelled from the body within minutes.

Steven Feinstein, M.D., a professor of medicine at Rush University in Chicago, said the study validates the vast benefits of using microbubble ultrasound contrast agents as a safe, convenient and effective diagnostic imaging tool. "The findings are extremely exciting and demonstrate that CEUS imaging improves patient care without exposing individuals to tissue diagnosis or ionizing radiation,” Feinstein added.

Wilson’s study utilized the Liver Imaging Reporting and Data System (LI-RADS), a tool radiologists use to classify liver tumors using computed tomography (CT), MR and CEUS imaging in patients with suspected liver cancer. Additional prospective studies are expected according to Yuko Kono, M.D., a professor of hepatology and gastroenterology at the University of California San Diego and a leader in the CEUS imaging field.

For more information: www.icus-society.org


Related Content

News | Digital Pathology

Sept. 24, 2026 — Leica Biosystems,has added two Paige digital pathology AI-enabled products from Tempus to its Aperio AI ...

Time September 25, 2026
arrow
News | CT Angiography (CTA)

Sept. 15, 2026 — A new study published in the Journal of the American College of Radiology (JACR) found that an ...

Time September 15, 2026
arrow
News | Lung Imaging

Sept. 8, 2026 – Brainomix and Endeavor BioMedicines recently presented positive results from the Brainomix AI-driven ...

Time September 09, 2026
arrow
News | Ultrasound Women's Health

Sept. 3, 2026 — Royal Philips has introduced the eV14-2v transvaginal transducer, expanding its obstetrics and ...

Time September 04, 2026
arrow
News | Ultrasound Imaging

Sept. 2, 2026 – Sonex Health and The Institute of Advanced Ultrasound Guided Procedures have announced publication of ...

Time September 04, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026— A new study from the Harvey L. Neiman Health Policy Institute found that the odds of imaging following an ...

Time September 01, 2026
arrow
News | Breast Imaging

Aug. 20, 2026 — Candelis, Inc. has announced a collaboration with GE HealthCare to support the distribution of Candelis ...

Time August 24, 2026
arrow
News | RSNA

Aug. 18, 2026 —The board of trustees of the Radiological Society of North America's (RSNA) Research & Education (R&E) ...

Time August 24, 2026
arrow
News | Clinical Trials

Aug.12, 2026 — Mendaera Inc. has announced results from a peer-reviewed study showing that its FDA-cleared Focalist ...

Time August 17, 2026
arrow
Subscribe Now